Tekla Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Tekla Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-117,717	Closed	-$2.49M	–	180
2023 Q1	$2.49M	Hold	117,717	–	–	0.09%	114
2022 Q4	$3M	Buy	+117,717	New	+$2.75M	0.11%	100
2022 Q3	–	Sell	-56,480	Closed	-$1.09M	–	181
2022 Q2	$1.09M	Hold	56,480	–	–	0.04%	132
2022 Q1	$982K	Buy	+56,480	New	+$951K	0.03%	147
2019 Q2	–	Sell	-143,438	Closed	-$753K	–	202
2019 Q1	$753K	Sell	143,438 -56,562	-28%	-$323K	0.03%	170
2018 Q4	$890K	Hold	200,000	–	–	0.04%	167
2018 Q3	$1.62M	Hold	200,000	–	–	0.06%	165
2018 Q2	$1.4M	Hold	200,000	–	–	0.05%	152
2018 Q1	$2.85M	Hold	200,000	–	–	0.11%	120
2017 Q4	$1.75M	Hold	200,000	–	–	0.07%	132
2017 Q3	$2.34M	Hold	200,000	–	–	0.08%	111
2017 Q2	$2.79M	Buy	+200,000	New	+$2.29M	0.1%	102

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Tekla Capital Management's SNDX Position: Q2 2023 in Review

Tekla Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2023, closing a stake of 117,717 shares — an estimated $2.49M sold.

Tekla Capital Management first reported a position in SNDX in Q2 2017 and held it in 12 quarters. The position peaked at $3M in Q4 2022. 166 funds tracked by Wall St. Rank hold SNDX as of Q2 2023.

Tekla Capital Management reported no remaining Syndax Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Tekla Capital Management sold 117,717 Syndax Pharmaceuticals shares in Q2 2023, an estimated $2.49M.
Tekla Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2017 and held it in 12 quarters.
Tekla Capital Management's Syndax Pharmaceuticals position peaked at $3M in Q4 2022.
166 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.